The full meeting summary from the FDA Rare Disease Patient-led Listening Session on CMT-SORD,
held on 4 August 2026. Fifty-two people took part, including representatives from four FDA
centers, the NIH, and the Reagan-Udall Foundation. Read it below, or download the PDF.
Changes how this site looks for you, and are saved on this device.
Be the first to know
Become a CureCMT insider
Research moves fast. Add your number and we will text you the things that matter most:
new treatment news, trial openings, and ways to take part before they fill up.